Table 6.
Concerns | Preferred Timing from End of Radiation to Expander to Implant Exchange | |||
---|---|---|---|---|
0–3 mo | 4–12 mo | >12 mo | P | |
Asymmetry | 53.50% | 40.50% | 45.90% | 0.244 |
Hematoma | 4.70% | 3.90% | 5.40% | 0.903 |
Mastectomy skin loss | 39.50% | 53.90% | 56.80% | 0.181 |
Severe capsular contracture | 83.70% | 74.30% | 86.50% | 0.129 |
Surgical site infection | 48.80% | 48.00% | 37.80% | 0.489 |
Wound dehiscence | 69.80% | 79.30% | 67.60% | 0.134 |
Concerns | Preferred Timing from End of Radiation to Expander Removal and Autologous Reconstruction | |||
0–3 mo | 4–12 mo | >12 mo | P | |
Asymmetry | 33.30% | 17.50% | 20.60% | 0.154 |
Donor vessel quality and dissection | 29.20% | 39.70% | 31.70% | 0.330 |
Fat necrosis | 25.00% | 17.80% | 27.00% | 0.205 |
Hematoma | 4.20% | 0.70% | 1.60% | 0.241 |
Mastectomy skin loss | 25.00% | 34.70% | 34.90% | 0.623 |
Poor cosmetic outcome | 16.70% | 26.60% | 36.50% | 0.130 |
Surgical site infection | 12.50% | 20.50% | 17.50% | 0.572 |
Tissue edema | 20.80% | 20.90% | 14.30% | 0.487 |
Tissue fibrosis | 54.20% | 42.40% | 34.90% | 0.249 |
Total/partial flap loss | 41.70% | 25.30% | 30.20% | 0.184 |
Wound dehiscence | 37.50% | 53.90% | 50.80% | 0.292 |